ARROWHEAD PHARMACEUTICALS, INC. Stockholders' Equity Attributable to Noncontrolling Interest
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Stockholders' Equity Attributable to Noncontrolling Interest of $512.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:MinorityInterest · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Noncontrolling Interest $512.00K.
- 2026-03-31: Stockholders' Equity Attributable to Noncontrolling Interest -$15.06M.
- 2025-12-31: Stockholders' Equity Attributable to Noncontrolling Interest -$5.72M.
- 2025-09-30: Stockholders' Equity Attributable to Noncontrolling Interest $37.36M.
| Period end | Stockholders' Equity Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $512.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | -$15.06M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$5.72M 10-Q · filed 2026-02-05 |
| 2025-09-30 | $37.36M 10-Q · filed 2026-08-04 |
| 2025-06-30 | -$2.51M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $904.00K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $3.49M 10-Q · filed 2025-02-10 |
| 2024-09-30 | $5.62M 10-K · filed 2025-11-25 |
| 2024-06-30 | $8.43M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $11.61M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $13.31M 10-Q · filed 2024-02-06 |
| 2023-09-30 | $15.82M 10-K · filed 2024-11-26 |
| 2023-06-30 | $17.16M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $18.33M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $19.33M 10-Q · filed 2023-02-06 |
| 2022-09-30 | $19.82M 10-K · filed 2023-11-29 |
| 2022-06-30 | $20.25M 10-Q · filed 2022-08-04 |
| 2021-09-30 | $0.00 10-K · filed 2022-11-28 |
| 2020-06-30 | -$555.19K 10-Q · filed 2020-08-05 |
| 2020-03-31 | -$555.19K 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$555.19K 10-Q · filed 2020-02-05 |
| 2019-09-30 | -$555.19K 10-K · filed 2020-11-23 |
| 2019-06-30 | -$555.19K 10-Q · filed 2019-08-05 |
| 2019-03-31 | -$555.19K 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$555.19K 10-Q · filed 2019-02-07 |
| 2018-09-30 | -$555.19K 10-K · filed 2019-11-25 |
| 2018-06-30 | -$555.19K 10-Q · filed 2018-08-07 |
| 2018-03-31 | -$555.19K 10-Q · filed 2018-05-08 |
| 2017-12-31 | -$555.19K 10-Q · filed 2018-02-09 |
| 2017-09-30 | -$555.19K 10-K · filed 2018-12-11 |
| 2017-06-30 | -$555.19K 10-Q · filed 2017-08-03 |
| 2017-03-31 | -$555.19K 10-Q · filed 2017-05-03 |
| 2016-12-31 | -$555.19K 10-Q · filed 2017-02-06 |
| 2016-09-30 | -$555.19K 10-K · filed 2017-12-12 |
| 2016-06-30 | -$555.19K 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$555.19K 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$555.19K 10-Q · filed 2016-02-09 |
| 2015-09-30 | -$555.19K 10-K · filed 2016-12-14 |
| 2015-06-30 | -$555.19K 10-Q · filed 2015-08-04 |
| 2015-03-31 | -$555.19K 10-Q · filed 2015-05-11 |
| 2014-12-31 | -$555.19K 10-Q · filed 2015-02-09 |
| 2014-09-30 | -$555.19K 10-K · filed 2015-12-14 |
| 2014-06-30 | -$555.10K 10-Q · filed 2014-08-12 |
| 2014-03-31 | -$1.86M 10-Q · filed 2014-05-06 |
| 2013-12-31 | -$1.82M 10-Q · filed 2014-02-04 |
| 2013-09-30 | -$1.76M 10-K · filed 2014-11-25 |
| 2013-06-30 | -$1.65M 10-Q · filed 2013-08-07 |
| 2013-03-31 | -$1.55M 10-Q · filed 2013-05-09 |
| 2012-12-31 | -$1.37M 10-Q · filed 2013-02-13 |
| 2012-09-30 | -$1.20M 10-K · filed 2013-12-18 |
| 2012-06-30 | -$916.66K 10-Q · filed 2012-08-13 |
| 2012-03-31 | -$669.11K 10-Q · filed 2012-05-08 |
| 2011-12-31 | -$420.23K 10-Q · filed 2012-02-09 |
| 2011-09-30 | -$226.94K 10-K · filed 2012-12-28 |
| 2011-06-30 | -$56.52K 10-Q · filed 2011-08-08 |
| 2010-09-30 | -$967.41K 10-K · filed 2011-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |